RxDoctor Payments Data

Stacy Konyar

Family · Winchester, VANPI 1972806404

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $30,758 of the $45,439 with a category attached, or 67.7%. 53 manufacturers reported payments, led by AbbVie at 49.2% of the total. Reporting peaked in 2021 at $18,258 and has fallen 85.9% since, to $2,579 in 2025. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$45,439in general payments, 2019–2025

Across 800 payments — averaging $56.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$22K
  • Biohaven Pharmaceuticals, Inc.$10K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • Lilly USA, LLC$1K
  • Biogen$1K
  • Pfizer$943
  • plus $7K from 47 others

What the payments were for

  • Speaking & faculty fees$30,75868%
  • Travel & lodging$1,1022%
  • Food & beverage$13,38829%
  • Education$1900%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,439 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$45,499
Medicare patients
99
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate11$19,890
Levothyroxine Sodium47$624
Albuterol Sulfate HfaAlbuterol Sulfate15$596
Bupropion XlBupropion Hcl12$541
Lisinopril49$488
Pantoprazole Sodium17$303
Pramipexole DihydrochloridePramipexole Di-Hcl18$293
Omeprazole24$259
Gabapentin22$222
Fluoxetine Hcl17$208
Rosuvastatin Calcium13$164
Tramadol Hcl15$145
Atorvastatin Calcium24$123
Amlodipine Besylate19$100
Allopurinol11$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$173$19,89011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →